成都华任康

Chengdu Huarenkang Biotechnology is a biopharmaceutical company based in Chengdu, China, specializing in the research and development of innovative small molecule drugs. Established in 2019, the company is a spin-off from the academic research of West China Hospital at Sichuan University, led by Professor Zeng Xiancheng. Huarenkang focuses on developing targeted therapies for oncology and autoimmune diseases, with a particular emphasis on kinase inhibitors and epigenetic modulators. The company's pipeline includes several pre-clinical programs targeting Janus kinase (JAK), Bruton's tyrosine kinase (BTK), and histone deacetylase (HDAC). Huarenkang aims to provide high-quality, affordable therapeutic solutions through its proprietary drug discovery platform. The company is located in the Chengdu High-tech Industrial Development Zone and is recognized as a technology-based small and medium-sized enterprise.